VRTX
Vertex Pharmaceuticals Inc.
$523.93
-2.10%
2026-10-23
About Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Key Fundamentals
P/E Ratio
30.61
Forward P/E
26.19
EPS (TTM)
$17.19
ROE
23.5%
Revenue Growth (YoY)
12.5%
Profit Margin
35.0%
Debt/Equity
9.77
Price/Book
6.58
Beta
0.32
Market Cap
$133.28B
Avg Volume (10D)
1.1M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$560.25
60D Low
$465.51
Avg Volume
1.2M
Latest Close
$523.93
Get breakout alerts for VRTX
Sign up for Breakout Scanner to receive daily notifications when VRTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Vertex Pharmaceuticals Inc. (VRTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors VRTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. VRTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.